The global insulin market is dominated by three companies: Eli Lilly, the French company Sanofi and the Danish firm Novo Nordisk.
In the past decade alone, U.S. insulin list prices have tripled, according to an analysis of data from IBM Watson Health
According to IBM Watson Health data, Sanofi’s popular insulin brand Lantus was $35 a vial when it was introduced in 2001; it’s now $270. Novo Nordisk’s Novolog was priced at $40 in 2001, and as of July 2018, it’s $289.
Stories of people rationing insulin and dying as a result continue to appear in the media.